The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 10, 2007, Pages 1193-1201

  Lopez Alcorocho J M ^a   Rodriguez Inigo E ^a   Castillo, I ^a   Castellanos, M E ^b   Pardo, M ^a   Bartolome J ^a   Quiroga, J A ^a   Carreno V ^a  

^a Fundacion para el Estudio de Las Hepatitis Virales   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER BIOPSY; LIVER CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIRUS GENOME; VIRUS INFECTIVITY;

ADULT; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENOME, VIRAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 34247505964     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03314.x     Document Type: Article

References (24)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 62.
2. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001 313 : 451 64.
3. World Health Organization. Hepatitis C. Wkly Epidemiol Rec 1997 72 : 65 9.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
5. Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004 41 : 474 81.
6. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Hepatitis C antiviral long-term treatment against Cirrhosis Trial Group: peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 : 1015 23.
7. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
8. Yuki N, Hayashi N, Kasahara A, et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995 22 : 457 63.
9. Garson JA, Brillanti S, Whitby K, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995 45 : 348 453.
10. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996 24 : 1034 40.
11. Rodriguez-Inigo E, Lopez-Alcorocho JM, Bartolomé J, Ortiz-Movilla N, Pardo M, Carreño V. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn 2005 7 : 535 43.
12. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991 13 : 372 4.
13. Bullock GC, Bruns DE, Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 2002 48 : 2147 54.
14. Rodriguez-Inigo E, Bartolomé J, de Lucas S, et al. Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Am J Pathol 1999 154 : 1877 81.
15. de Lucas S, Bartolomé J, Rodriguez-Inigo E, et al. Distribution of hepatitis C virus infection in liver biopsies from children and adults with chronic hepatitis C. J Med Virol 2001 64 : 1 5.
16. Gosalvez J, Rodriguez-Inigo E, Ramiro-Diaz JL, et al. Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis. Hepatology 1998 27 : 1428 34.
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993 39 : 561 77.
18. Yuki N, Matsumoto S, Tadokoro K, Mochizuki K, Kato M, Yamaguchi T. Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis C. J Hepatol 2006 44 : 302 9.
19. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 : 103 7.
20. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004 24 : 25 31.
21. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa.2a (40 KD)/ribavirin. J Hepatol 2005 43 : 425 33.
22. National Institute of Health. Consensus development conference panel statement: management of hepatitis C. Hepatology 1997 26 (Suppl. 1 2S 10.
23. The British Society of Gastroenterology. Guidelines on the use of liver biopsy in clinical practice. Gut 1999 45 (Suppl. 4 1 11.
24. European Association for the Study of the Liver. Consensus statement EASL: International Conference on Hepatitis C. J Hepatol 1999 31 (Suppl. 1 3 8.